Rhythm EVP Exercises Options, Sells 75,834 Shares
Rhythm Pharmaceuticals EVP Jennifer Kayden Lee reported multiple transactions in company equity on August 13, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Rhythm Pharmaceuticals EVP Jennifer Kayden Lee reported multiple transactions in company equity on August 13, 2026. She exercised stock options covering 56,601 shares of common stock at exercise prices of $24.29 and $6.80 per share, receiving the corresponding common shares. She then sold 75,834 shares of common stock at a price of $117.3818 per share. All exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2026.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
5 txns
Insider
Lee Jennifer Kayden
Role
EVP, Head of North America
Sold
75,834 shs ($8.90M)
Approx. gross sale proceeds
$8.90M
Approx. exercise cost
$997K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (Right to Buy) F1, F2 | 35,000 | $0.00 | $0.00 |
| Exercise | Stock Options (Right to Buy) F1, F3 | 21,601 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 35,000 | $24.29 | $850K |
| Exercise | Common Stock F1 | 21,601 | $6.80 | $147K |
| Sale | Common Stock F1 | 75,834 | $117.3818 | $8.90M |
Holdings After Transaction:
Stock Options (Right to Buy) — 36,283 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.
- F2. The stock options were granted on November 9, 2020. 25% of the shares subject to the option vested and become exercisable on November 9, 2021 and the remaining 75% of the shares subject to the option vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.
- F3. The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Key Figures
Shares sold: 75,834 shares
Sale price per share: $117.3818
Options exercised: 56,601 shares
+5 more
8 metrics
Shares sold
75,834 shares
Common stock sale on August 13, 2026
Sale price per share
$117.3818
Price for 75,834 common shares sold
Options exercised
56,601 shares
Total underlying common shares from option exercises
Option exercise price 1
$24.29
Exercise price for 35,000 options granted November 9, 2020
Option exercise price 2
$6.80
Exercise price for 21,601 options granted February 9, 2022
10b5-1 plan adoption date
May 14, 2026
Date reporting person adopted Rule 10b5-1 trading plan
Option expiration 1
November 9, 2030
Expiration date for 2020 stock option grant
Option expiration 2
February 8, 2032
Expiration date for 2022 stock option grant
Key Terms
Rule 10b5-1 trading plan, Stock Options (Right to Buy), Exercise or conversion of derivative security, Common Stock, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The exercises and sales ... were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Options (Right to Buy) financial
"security_title: Stock Options (Right to Buy) with underlying common stock"
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
Common Stock financial
"underlying_security_title: Common Stock for exercised options"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
expiration date financial
"expiration_date: 2030-11-09 and 2032-02-08 for option grants"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Rhythm Pharmaceuticals (RYTM) executive Jennifer Kayden Lee report in this Form 4?
Jennifer Kayden Lee reported option exercises for 56,601 shares and the sale of 75,834 common shares of Rhythm Pharmaceuticals stock, with all transactions executed under a previously adopted Rule 10b5-1 trading plan.
How many Rhythm Pharmaceuticals (RYTM) options did the EVP exercise and at which strike prices?
She exercised stock options covering 56,601 shares of Rhythm Pharmaceuticals common stock, with exercise prices of $24.29 and $6.80 per share, converting these options into common stock before the reported sale transaction.
Were the reported Rhythm Pharmaceuticals (RYTM) transactions made under a Rule 10b5-1 plan?
Yes, the filing states that all exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2026, indicating a pre-arranged trading program.
What is the role of the reporting person at Rhythm Pharmaceuticals (RYTM)?
The reporting person, Jennifer Kayden Lee, serves as EVP, Head of North America at Rhythm Pharmaceuticals. The reported transactions involve her directly held options and common stock in the company.
What are the vesting details of the Rhythm Pharmaceuticals (RYTM) options exercised?
One option grant from November 9, 2020 vested 25% on November 9, 2021, with the remainder vesting quarterly thereafter; another grant from February 9, 2022 vested in 16 equal quarterly installments after grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
